Device Trial Radar · NCT05042453
Long-term Evaluation of the Efficacy and Safety of Splentis for the Treatment of Primary Apical Pelvic Organ Prolapse
Last checked: Nov 20, 2026Latest source record: Nov 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Dec 19, 2022
Primary completion
Jul 2026
Study completion Jul 2030
Sponsor
- Lead sponsor
- PromedonNot on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 13, 2021
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective, multi center cohort trial aims to evaluate the efficacy and safety of hysteropexy using Splentis via the vaginal route in primary uterine prolapse
Conditions
- Pelvic Organ Prolapse
Interventions
Splentis® POP Tissue Anchoring SystemDevice
Anterior cervicopexy with bilateral sacrospinous ligament fixation using Splentis
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cure of apical pelvic organ prolapseTime frame: 12 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
DRK Hospital Chemnitz-Rabenstein
Chemnitz, Germany · Recruiting
Helios Hospital Erfurt, Department of gynaecology
Erfurt, Germany · Recruiting
University Hospital Freiburg
Freiburg im Breisgau, Germany · Recruiting
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.